A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Alendronic acid/guanidine dextran conjugate (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors DexTech Medical
- 30 Jan 2018 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 30 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 25 Jul 2017 Planned End Date changed from 1 Apr 2019 to 1 Oct 2019.